CapitalBio Technology Co., Ltd.

CapitalBio Technology Co., Ltd. (abbreviated “CapitalBio”) is the industrialization platform of the CapitalBio Corporation and the Beijing National Engineering Research Center for Biochips. CapitalBio has always adhered to independent innovation and achievement transformation and has a complete industrial chain integrating R&D, production, sales, and thrid-party independent medical laboratory services; and responds to the national policy of “prevention first.” The health policy integrates modern medicine and traditional Chinese medicine to form a large health industry section that includes health products, health management, medical rehabilitation, and big data. CapitalBio, based on a comprehensive biotechnology platform, provides instruments and equipment, supporting reagents and consumables, scientific research service outsourcing, experimental overall solutions, and so on. A variety of products and services have been exported to more than 30 countries and regions in North America, Europe, Asia, and so on. The biochip-related products developed have twice won the National Technology Invention Award’s second prize.

CapitalBio has developed a series of molecular detection products for hereditary diseases, infectious diseases, tumors, individualized medicine, disease susceptibility gene detection, and other urgently needed clinical products, as well as product services and overall solutions for accurate diagnosis and health. CapitalBio, a leading enterprise in the field of life sciences in China, has always adhered to the concept of “committed to technological innovation and realizing health dreams,”creating a full life cycle, comprehensive health service system, and a new medical and health service model suitable for China’s national conditions. Diversified health products benefit people’s livelihoods and help to build a “Healthy China”.